MX2020008024A - Compuestos de indol carboxamida útiles como inhibidores de cinasas. - Google Patents

Compuestos de indol carboxamida útiles como inhibidores de cinasas.

Info

Publication number
MX2020008024A
MX2020008024A MX2020008024A MX2020008024A MX2020008024A MX 2020008024 A MX2020008024 A MX 2020008024A MX 2020008024 A MX2020008024 A MX 2020008024A MX 2020008024 A MX2020008024 A MX 2020008024A MX 2020008024 A MX2020008024 A MX 2020008024A
Authority
MX
Mexico
Prior art keywords
kinase
compounds
inhobitors
compounds useful
indole carboxamides
Prior art date
Application number
MX2020008024A
Other languages
English (en)
Other versions
MX393057B (es
Inventor
Scott Hunter Watterson
Saleem Ahmad
Joseph A Tino
Qingjie Liu
Andrew J Tebben
Douglas G Batt
Hua Gong
Khehyong Ngu
Weiwei Guo
John E Macor
Bertrand Myra Beaudoin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020008024A publication Critical patent/MX2020008024A/es
Publication of MX393057B publication Critical patent/MX393057B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Se revelan los compuestos de la fórmula (I): (VER FÓRMULA) o una de sus sales, en donde: X es CR2 o N; RI, R2, R2, R4 y A se definen en la presente. También se revelan métodos de uso de tales compuestos como inhibidores de la tirosina cinasa de Bruton (Btk) y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son de utilidad en el tratamiento, prevención o lentificación de la progresión de enfermedades o trastornos en una variedad de áreas terapéuticas, tales como enfermedades autoinmunes y enfermedad vascular.
MX2020008024A 2014-10-24 2015-10-23 Compuestos de indol carboxamida útiles como inhibidores de cinasas. MX393057B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068225P 2014-10-24 2014-10-24
PCT/US2015/057055 WO2016065226A1 (en) 2014-10-24 2015-10-23 Indole carboxamides compounds useful as kinase inhobitors

Publications (2)

Publication Number Publication Date
MX2020008024A true MX2020008024A (es) 2022-06-10
MX393057B MX393057B (es) 2025-03-24

Family

ID=54427877

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005259A MX377837B (es) 2014-10-24 2015-10-23 Compuestos de indol carboxamida utiles como inhibidores de cinasas.
MX2020008024A MX393057B (es) 2014-10-24 2015-10-23 Compuestos de indol carboxamida útiles como inhibidores de cinasas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005259A MX377837B (es) 2014-10-24 2015-10-23 Compuestos de indol carboxamida utiles como inhibidores de cinasas.

Country Status (35)

Country Link
US (8) US9688629B2 (es)
EP (2) EP3461821B1 (es)
JP (1) JP6517928B2 (es)
KR (2) KR102001745B1 (es)
CN (2) CN107108583B (es)
AR (2) AR102426A1 (es)
AU (2) AU2015335694B2 (es)
CA (1) CA2965517C (es)
CL (1) CL2017000992A1 (es)
CO (1) CO2017004481A2 (es)
CY (2) CY1123401T1 (es)
DK (2) DK3209656T3 (es)
EA (2) EA032277B1 (es)
ES (2) ES2795366T3 (es)
HR (2) HRP20200819T1 (es)
HU (2) HUE050592T2 (es)
IL (2) IL251797B (es)
LT (2) LT3461821T (es)
MA (2) MA40301B1 (es)
ME (2) ME03807B (es)
MX (2) MX377837B (es)
MY (2) MY188048A (es)
PE (2) PE20170695A1 (es)
PH (2) PH12017500725B1 (es)
PL (2) PL3461821T3 (es)
PT (2) PT3461821T (es)
RS (2) RS60629B1 (es)
SG (3) SG10201903578VA (es)
SI (2) SI3209656T1 (es)
SM (2) SMT202000317T1 (es)
TN (2) TN2017000119A1 (es)
TW (2) TWI744218B (es)
UY (1) UY36371A (es)
WO (1) WO2016065226A1 (es)
ZA (1) ZA201804893B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
UA119870C2 (uk) 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
TN2017000158A1 (en) 2014-10-24 2018-10-19 Bristol Myers Squibb Co Carbazole derivatives
CA2965516A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
RS61504B1 (sr) 2014-10-24 2021-03-31 Takeda Pharmaceuticals Co Jedinjenja heteroarila za lečenje oftalmičkih bolesti
EP3433246B1 (en) 2016-03-24 2022-05-04 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
AU2017281286B2 (en) 2016-06-20 2021-05-20 Incyte Corporation Crystalline solid forms of a bet inhibitor
PT3507282T (pt) * 2016-09-02 2020-12-23 Bristol Myers Squibb Co Processo para a preparação de compostos de indol carboxamida
GB201616511D0 (en) * 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
JP7286755B2 (ja) 2018-07-31 2023-06-05 ロクソ オンコロジー， インコーポレイテッド （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
EP4061341A4 (en) * 2019-11-22 2024-04-10 The Regents of the University of California CASPASE6 INHIBITORS AND USES THEREOF
WO2021112987A1 (en) * 2019-12-04 2021-06-10 Aptinyx Inc. Methods of treating cognitive impairment associated with neurodegenerative disease
AU2021283916A1 (en) * 2020-06-02 2023-01-05 Vidya Therapeutics, Inc. Kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022028527A1 (zh) * 2020-08-07 2022-02-10 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
US20230265083A1 (en) * 2020-08-10 2023-08-24 Prelude Therapeutics Incorporated Heterocycle CDK Inhibitors And Their Use Thereof
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2022089620A1 (zh) * 2020-10-30 2022-05-05 苏州晶云药物科技股份有限公司 吲哚基甲酰胺类化合物的新晶型及其制备方法
CN117015528A (zh) * 2021-01-12 2023-11-07 Gb005股份有限公司 作为激酶抑制剂的吲哚衍生物
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
CN115368310B (zh) * 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US20240383871A1 (en) 2021-08-30 2024-11-21 Bristol-Myers Squibb Company Compound useful for pet-imaging of bruton’s tyrosine kinase
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN115010665A (zh) * 2022-08-05 2022-09-06 山东省食品药品检验研究院 一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
EA014956B1 (ru) 2004-12-17 2011-04-29 ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
MX2007012448A (es) * 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
UA99699C2 (ru) * 2005-06-30 2012-09-25 Смитклайн Бичам Корпорейшн Производные индолкарбоксамида и фармацевтическая композиция, которая их содержит
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8518964B2 (en) 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
US8263648B2 (en) 2006-09-11 2012-09-11 Mylan Laboratories Ltd. Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10
EP2270200A3 (en) 2006-09-11 2011-07-13 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
EP2144630A2 (en) 2007-04-27 2010-01-20 AstraZeneca AB Chk1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
CN102164604A (zh) 2008-07-24 2011-08-24 百时美施贵宝公司 用作激酶调节剂的稠合杂环化合物
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
BRPI0922565A2 (pt) * 2008-12-19 2015-12-15 Bristol Myers Squibb Co compostos de carbazol carboxamida úteis como inibidores de cinase
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
EP2415184B1 (en) 2009-02-13 2019-04-10 Nextivity, Inc. Remote control for booster
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
EP2582668B1 (en) 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
EP2702042A1 (en) 2011-04-28 2014-03-05 Bristol-Myers Squibb Company Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
CA2834077A1 (en) 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2013008095A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
JP6223452B2 (ja) * 2012-09-07 2017-11-01 ノバルティス アーゲー インドールカルボキサミド誘導体およびその使用
CN105473573B (zh) 2013-06-25 2018-03-16 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
MX355943B (es) * 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.

Also Published As

Publication number Publication date
EP3209656B1 (en) 2020-04-01
KR20180132167A (ko) 2018-12-11
TN2017000119A1 (en) 2018-07-04
US20190119245A1 (en) 2019-04-25
US20190248760A1 (en) 2019-08-15
HRP20200819T1 (hr) 2020-08-07
MX2017005259A (es) 2017-07-26
SMT202000412T1 (it) 2020-09-10
MY188048A (en) 2021-11-12
BR112017007956A2 (pt) 2017-12-19
MX393057B (es) 2025-03-24
MA40301A1 (fr) 2019-03-29
ES2795366T3 (es) 2020-11-23
US20230192645A1 (en) 2023-06-22
UY36371A (es) 2016-04-29
US10329274B2 (en) 2019-06-25
PE20190710A1 (es) 2019-05-17
DK3461821T3 (da) 2020-08-17
CN110511209A (zh) 2019-11-29
RS60629B1 (sr) 2020-09-30
CY1123395T1 (el) 2021-12-31
IL262206B (en) 2020-07-30
ME03807B (me) 2021-04-20
US20200165222A1 (en) 2020-05-28
CL2017000992A1 (es) 2017-11-17
US20170260160A1 (en) 2017-09-14
PL3461821T3 (pl) 2020-10-19
AU2019283921A1 (en) 2020-01-16
CA2965517A1 (en) 2016-04-28
TWI744218B (zh) 2021-11-01
AU2015335694A1 (en) 2017-06-08
LT3461821T (lt) 2020-08-10
TN2018000218A1 (en) 2019-10-04
US9920031B2 (en) 2018-03-20
EA034931B1 (ru) 2020-04-08
CO2017004481A2 (es) 2017-08-10
PL3209656T3 (pl) 2020-12-14
US20170066740A1 (en) 2017-03-09
TW201900612A (zh) 2019-01-01
PT3461821T (pt) 2020-08-05
HUE050592T2 (hu) 2020-12-28
WO2016065226A1 (en) 2016-04-28
AR120317A2 (es) 2022-02-09
PE20170695A1 (es) 2017-05-26
MA40301B1 (fr) 2019-12-31
MX377837B (es) 2025-03-11
EA201790740A1 (ru) 2017-08-31
TW201630880A (zh) 2016-09-01
EP3209656A1 (en) 2017-08-30
SG10201903579SA (en) 2019-05-30
US9688629B2 (en) 2017-06-27
NZ731946A (en) 2021-02-26
US11623921B2 (en) 2023-04-11
MY195561A (en) 2023-02-02
KR102001745B1 (ko) 2019-07-18
AU2015335694B2 (en) 2020-04-02
US10604504B2 (en) 2020-03-31
PT3209656T (pt) 2020-06-08
EP3461821B1 (en) 2020-05-13
SG10201903578VA (en) 2019-05-30
EA032277B1 (ru) 2019-05-31
SI3461821T1 (sl) 2020-09-30
US9802915B2 (en) 2017-10-31
US20160115126A1 (en) 2016-04-28
CN110511209B (zh) 2022-07-05
PH12020500265A1 (en) 2021-02-22
ME03740B (me) 2021-01-20
LT3209656T (lt) 2020-07-27
HUE050706T2 (hu) 2020-12-28
MA47043B1 (fr) 2021-09-30
MA47043A1 (fr) 2021-03-31
SMT202000317T1 (it) 2020-07-08
JP6517928B2 (ja) 2019-05-22
ES2809974T3 (es) 2021-03-08
KR20170061175A (ko) 2017-06-02
JP2017531679A (ja) 2017-10-26
TWI743401B (zh) 2021-10-21
NZ754113A (en) 2021-02-26
PH12017500725A1 (en) 2017-10-09
PH12017500725B1 (en) 2017-10-09
IL251797B (en) 2020-07-30
EA201892207A1 (ru) 2019-02-28
WO2016065226A8 (en) 2017-04-27
CY1123401T1 (el) 2021-12-31
IL251797A0 (en) 2017-06-29
RS60312B1 (sr) 2020-07-31
EP3461821A1 (en) 2019-04-03
HRP20201146T1 (hr) 2020-10-30
CA2965517C (en) 2023-05-02
AR102426A1 (es) 2017-03-01
SI3209656T1 (sl) 2020-07-31
KR102030305B1 (ko) 2019-10-08
US20210107891A1 (en) 2021-04-15
SG11201703188QA (en) 2017-05-30
CN107108583B (zh) 2020-11-13
IL262206A (en) 2018-11-29
AU2019283921B2 (en) 2021-01-07
CN107108583A (zh) 2017-08-29
DK3209656T3 (da) 2020-07-13
ZA201804893B (en) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2020008024A (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX2017002206A (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
NI201500140A (es) Compuestos y composiciones terapéuticos
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
EA201790745A1 (ru) Трициклические соединения
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CR20150211A (es) Compuestos diméricos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
EA201790870A1 (ru) Трициклические атропоизомерные соединения
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.